SB-480848 is a reversible lipoprotein-associated phospholipase A 2 inhibitor under development by GlaxoSmithKline for the potential treatment of atherosclerosis. Phase II trials with SB-480848 are currently underway.
MSU Digital Commons Citation
Rotella, David, "SB-480848 (Glaxosmithkline)" (2004). Department of Chemistry and Biochemistry Faculty Scholarship and Creative Works. 266.